The need for better antifungal therapy is commonly accepted in view of the high mortality
rates associated with systemic infections, the low number of available antifungal classes …

Fungal infections have aroused much interest over the last years because of their
involvement in several human diseases. Immunocompromission due to transplant-related …

The utility of clinically available antifungals is limited by their narrow spectrum of activity,
high toxicity, and emerging resistance. Antifungal drug discovery has always been a …

During the past two decades the frequencies and types of life-threatening fungal infections
have increased dramatically in immunocompromised patients (7, 220, 232, 282). Several …

In recent years, incidences of invasive fungal infections have greatly increased, especially in
immunosuppressed patients, but most today's antifungal drugs are not completely effective …

Invasive, life-threatening fungal infections are an important cause of morbidity and mortality,
particularly for patients with compromised immune function. The number of therapeutic …

With the increasing morbidity and mortality of invasive fungal infections and the emergence
of severe antifungal drug resistance, new drug targets and novel antifungal agents are …

Invasive candidiasis (IC) can affect individuals with various underlying diseases hospitalized
in different parts of hospitals. In recent decades, IC has caused 27–55% mortality in general …

Invasive mycoses have become important causes of morbidity and mortality in
immunocompromised patients. New approaches for antifungal therapy are required to meet …

The high rates of morbidity and mortality caused by fungal infections are associated with the
current limited antifungal arsenal and the high toxicity of the compounds. Additionally …